California Health Benefits Review Program

Bridging the Divide: Lessons Learned Providing Evidence-Based Analysis to the California Legislature

Faculty at the UC Berkeley School of Public Health

Garen Corbett
Director





CHBRP: BRIDGING ACADEMIA & LEGISLATURE

Take-Aways from my 10 Minutes:

- Impact: How our work is "used" in the policy analysis process?
- Our structure that allows this bridge to work?
- How one can bring objective, timely, evidence-based information to the Legislature
- What areas of expertise are leveraged?

What is CHBRP?

- ➤ Independent, analytic resource (in statute) housed at UC to support the Legislature, grounded in objective policy analysis.
- ➤ Multi-disciplinary: drawing from faculty & researchers across the University of California.
- ➤ We provides rapid, <u>evidence-based</u> information to the Legislature, leveraging faculty expertise since 2003. Moved to UC Berkeley in December of 2017.
- ➤ Neutral and unbiased analysis of introduced bills at the request of the Legislature

HOW CHBRP WORKS

- ➤ Upon receipt Legislature's request, CHBRP convenes multidisciplinary, analytic teams to provide rigorous, objective analysis *before* policy committee hearing.
- > CHBRP staff manage and facilitates:
 - the teams, policy context, ensures reports come together as a cohesive whole.
 - CHBRP staff manage external relationships, contracts, administrative operations.

CHBRP Analyses Provide:

Policy Context

Whose health insurance would have to comply?

Are related laws already in effect?

Medical Effectiveness

Which services and treatments are most relevant?

Does evidence indicate impact on outcomes?

Impacts

Would benefit coverage, utilization, or cost change?

Would the public's health change?


KEY DESIGN FEATURES OF CHBRP: LESSONS

- > States can deepen and leverage partnerships with public universities in legislative process
- Ensure impartiality/ objectivity/ strong COI are essential
- The Legislature needs to "Freeze legislation" for analysis period and find or secure a designated revenue source.
- ➤ Collaboration and Speed are *essential!*
 - 60 Days: "Blessing and Curse". Need robust tools/process
 - Peer review, feedback, and drafts create intense bursts of productively and effort

KEY DESIGN FEATURES OF CHBRP: LESSONS

- > Continuous quality improvement
- Engagement with users and stakeholders.
- > Year-round staff essential for maintaining institutional memory, tools, emphasis on Quality and Accuracy: Flexibility
- Faculty/researchers have stake and commitment to long-term success of the program. They see IMPACT of their work.
- ➤ Develop robust templates, timelines, and internal processes that ensure smooth flow

CHBRP's Website: www.chbrp.org




California Health Benefits Review Program

Rapid Analysis

Adara Citron
Principal Policy Analyst



CHBRP's 60-Day or Less Timeline



Analytic Teams

- CHBRP Staff (based at UC Berkeley)
- Task Force of faculty and researchers
 - Medical Effectiveness Team
 - Cost Team
 - Public Health Team
- Actuarial firm: Milliman, Inc.
- Librarians
- Content Experts

External Reviewers:

National Advisory Council

Analytic Sections

Medical Effectiveness

What services/treatments are included?

Do they work? What studies have been done?



Cost Projections

Will enrollees use it?

How much will it cost?



Public Health Impacts

What impacts on the community's overall health?

What are the health outcomes?

Actuarial Model, Example Table 1

Table 1. SB 600 Impacts on Benefit Coverage, Utilization, and Cost, 2020

	Baseline	Postmandate	Increase/ Decrease	Percentag Change
enefit coverage				
Total enrollees with				
health insurance subject to state-level				
benefit mandates (a)	24,490,000	24,490,000	0	0
Total enrollees with				
health insurance subject to SB 600	16,899,000	16,899,000	0	0
Percentage of	,,	,		
enrollees with health				
insurance subject to SB 600	69%	69%	0	C
Number of enrollees				
with fertility				
preservation coverage fully compliant with SB				
600	158,992	16,899,000	16,740,008	10,529
Percentage of				
enrollees with fertility preservation coverage				
fully compliant SB 600	0.94%	100%	99%	10,529
tilization and unit cost				
	f child-bearing age with	cancer diagnosis where	treatment might re	esult in
iatrogenic infertility				
Male	2,553	2,553	0	(
Female	3,799	3,799	0	(
Total	6,352	6,352	0	0
Number of enrollees w	ith cancer using cryopre	eservation covered by in	surance	
E				
Embryo	2	227	225	11,955
Mature oocyte	16	227 734	225 718	
				4,601
Mature oocyte Sperm	16	734 792	718 775	11,955 4,601 4,650
Mature oocyte Sperm	16 17	734 792	718 775	4,601 4,650
Mature oocyte Sperm Number of enrollees w	16 17 vith cancer using cryopre	734 792 eservation <u>not covered</u> b	718 775 by insurance	4,601 4,650 -100
Mature oocyte Sperm Number of enrollees w Embryo Mature oocyte	16 17 vith cancer using cryopre 102	734 792 eservation <u>not covered</u> b	718 775 by insurance -102	4,601 4,650 -100
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm	16 17 vith cancer using cryopre 102 326 639	734 792 eservation <u>not covered</u> b 0	718 775 by insurance -102 -326	4,601
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo	16 17 vith cancer using cryopre 102 326 639 preservation procedure	734 792 eservation not covered b 0 0	718 775 by insurance -102 -326 -639	4,601 4,650 -100
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo Embryo	16 17 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	734 792 servation <u>not covered</u> b 0 0 0 0	718 775 ry insurance -102 -326 -639	4,601 4,650 -100 -100 -100
Mature oocyte Sperm Number of enrollees w Embryo Mature oocyte Sperm Average cost per cryo Embryo Mature oocyte	16 17 vith cancer using cryopre 102 326 639 preservation procedure \$11,254 \$10,078	734 792 servation not covered b 0 0 0 0 \$11,254 \$10,078	718 775 ry insurance -102 -326 -639 0	4,601 4,650 -100 -100 -100
Mature oocyte Sperm Number of enrollees w Embryo Mature oocyte Sperm Average cost per cryo Embryo Mature oocyte Sperm	16 17 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	734 792 servation <u>not covered</u> b 0 0 0 0	718 775 ry insurance -102 -326 -639	4,601 4,650 -100 -100 -100
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm Sperm Average cost per cryo Embryo Mature occyte Sperm spenditures	16 17 vith cancer using cryopre 102 326 639 preservation procedure \$11,254 \$10,078	734 792 servation not covered b 0 0 0 0 \$11,254 \$10,078	718 775 ry insurance -102 -326 -639 0	4,601 4,650 -100 -100 -100
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm kyenditures Premiums by payer	16 17 vith cancer using cryopre 102 326 639 preservation procedure \$11,254 \$10,078	734 792 eservation not covered b 0 0 0 \$11,254 \$10,078	718 775 ry insurance -102 -326 -639 0 0	4,601 4,650 -100 -100 -100
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm spenditures Premiums by payer Private employers for	16 17 vith cancer using cryopre 102 326 639 preservation procedure \$11,254 \$10,078	734 792 servation not covered b 0 0 0 0 \$11,254 \$10,078	718 775 ry insurance -102 -326 -639 0	4,601 4,650 -100 -100 -100
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm kyenditures Premiums by payer	16 17 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	734 792 eservation not covered to 0 0 0 \$11,254 \$10,078 \$468	718 775 ny insurance -102 -326 -639 0 0 0	4,601 4,650 -100 -100 -100 ((()
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm Sperm Sperm Conditional S	16 17 vith cancer using cryopre 102 326 639 preservation procedure \$11,254 \$10,078	734 792 eservation not covered b 0 0 0 \$11,254 \$10,078	718 775 ry insurance -102 -326 -639 0 0	4,60° 4,65° -100° -100° -100° (0.006°
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm Copenditures Premiums by payer Private employers for group insurance CalPERS HMO employer expenditures (c) (b)	16 17 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	734 792 eservation not covered b 0 0 0 \$11,254 \$10,078 \$468 \$86,444,142,000 \$3,098,822,000	718 775 ry insurance -102 -326 -639 0 0 0 \$5,767,000 \$271,000	4,601 4,656 -100 -100 -100 ((()
Mature occyte Sperm Number of enrollees w Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm Average cost per cryo Embryo Mature occyte Sperm Sperm Sperm Conditional S	16 17 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	734 792 eservation not covered to 0 0 0 \$11,254 \$10,078 \$468	718 775 ny insurance -102 -326 -639 0 0 0	4,60° 4,65° -100° -100° -100° (0.006°

How Analyses are Completed

- Analytic methods
 (http://chbrp.org/analysis
 methodology/index.php
- Templates/ guidance documents
- Detailed timeline
- Communication

BACKGROUND ON ST/TREATMENT/SERVICE/CONDITION/DISEASE The background section should provide broad, contextual information about the disease/condition/provider/intervention, regardless of health insurance while the PH section only describes specific changes attributable to the proposed mandate. Insert paragraph(s) describing the subject of the bill (i.e., disease/condition/provider/intervention). This may include the history of the disease/condition, a basic clinical description or characteristics, and/or causes of disease. Review of applicable treatments should be decided by the bill team (ME and PH). List any limitations to the scope of what is considered part of the disease or condition for the purposes of the Tame of Disease/Condition Prevalence in California esent information about the incidence/prevalence of the disease or condition and, when agreed to by bill team, the use of treatment or intervention overall. Prevalence rates are generally presented in table form, by demographic characteristics (i.e., race/ethnicity, age, gender, income, etc.), preceded by a short summary of findings. This section notes differences and reserves the disparities discussion for the next section. Disparities cannot necessarily be discerned by prevalence rates alone (which may be unadjusted and/or not statistically significant). The following table describes the prevalence of x by key demographic age, gender, income, etc.) Table 1. Prevalence of Disease/Condition by Key De ource: California Health Benefits Review Program, 2020 Note: This would be a general note that applies to the entire table. * Use an asterisk (*) without parentheses if goly, one such note is needed. In the table, the asterisk is set closed (i.e., no space tween the symbol and the text), but in the table notes, there is a space separating it from the following text. (a) This would indicate a note applicable to a certain line in a table with more than one such note. Use lowercase letters [i.e., (a), (b) (c)) with parentheses. In the table, use a space before to separate it from the text; in the note in the table footer, use a space after o not use numbers for notes, as they could be confused with main-text footnotes. Key: Define all acronyms and abbreviations here (not in the table), even if defined elsewhere, and set in alphabetical order, e.g., CDI = California Department of Insurance; DMHC = Department of Managed Health Care; HMO = health maintenance organization

Analysis of California Assembly/Senate Bill

Key Takeaways

In order to complete analyses within 60 days, CHBRP:

- Has existing contracts with faculty and researchers across the UC system
- Clearly defines section content and methods
- Provides tools to complete actions quickly

California Health Benefits Review Program

Resources for Faculty and Students

Ana Ashby Policy Analyst



CHBRP CAN SUPPORT FACULTY AND STUDENTS THROUGH:

- > Guest lectures on current policy topics
- ➤ Analyses, resources, and other products
- > Internships and assistantships

GUEST LECTURES

- ➤ UCSD Example: Independent Study in Health Policy
- > Possible topics:
 - ➤ Health Insurance in California 101
 - > Test/Treatments/Services that have interested the Legislature
 - > Components to independent analyses
 - > Real-world uses for literature reviews



ANALYSES, RESOURCES, AND OTHER PRODUCTS



Date	Торіс	Event	
		2019	
September 13, 2019	Review of 2019-2020 California State Budget	CHBRP Faculty Task Force Meeting	
February 6, 2019	2019 CHBRP Annual Legislative Briefing Presentations	CHBRP Legislative Briefing	

Resource:

Health Insurance Benefit Mandates in California State and Federal Law

January 2, 2019

California Health Benefits Review Program

Issue Brief:

Estimates of Sources of Health Insurance in California for 2020

California Health Benefits Review Program University of California, Berkeley MC 3116 Berkeley, CA 94720-3116 T: (510) 664-5306

SUMMER INTERNSHIPS



- ➤ Master's or Doctoral candidates
- ➤ 40 hours per week, paid
- > Bill tracking
- Regulatory updates
- Stakeholder meetings
- Independent projects



ASSISTANTSHIPS



- Graduate/undergraduate students
- > 15-20 hours per week, paid
- > Bill tracking
- Social media updates
- > Stakeholder meetings
- > Administrative Support





Questions? Want more info? www.chbrp.org

Contacts:

Garen Corbett, Director glcorbett@berkeley.edu

John Lewis, Associate Director john.lewis@berkeley.edu

Adara Citron, Principal Policy Analyst adara.citron@berkeley.edu

Ana Ashby, Policy Analyst ana.ashby@berkeley.edu

Follow CHBRP:





